Lugon Jocemir R, Gordan Pedro A, Thomé Fernando S, Lopes Antonio A, Watanabe Yoshimi J A, Tzanno Carmen, Sesso Ricardo C
Universidade Federal Fluminense, Niterói, RJ, Brazil.
Universidade Estadual de Londrina, Londrina, PR, Brazil.
Int J Nephrol. 2018 Mar 5;2018:9894754. doi: 10.1155/2018/9894754. eCollection 2018.
The methods and initial results of a web-based platform to collect data from patients receiving maintenance dialysis in Brazil are reported.
Companies providing management software for dialysis centers adapted their system to comply with a formulary of the Brazilian Society of Nephrology. Baseline and follow-up individual patients' data were transmitted via Internet on monthly bases to the coordinating center from 2011 to 2017.
73 dialysis centers provided information of 24,930 patients: 57% were male, 28% were 64 years old or older, and 13% were overweight/obese. Median dialysis vintage was 28 months. Hemodialysis was the most frequent initial therapy (93%) with venous catheters used in 64% of cases. Conventional hemodialysis remained the main current therapy (90%). Seropositivity for hepatitis C, hepatitis B, and HIV was 2.7%, 1.1%, and 0.5%, respectively. Erythropoietin (53.9%), iron (35.1%), and sevelamer (23.4%) were the most used medications. Hemoglobin < 100 g/L and serum P > 1.74 mmol/L were present in 33.1% and 36.6% of the cases, respectively. The 5-year survival of incident cases ( = 7,538) was 57%.
The initiative represents an innovative strategy to collect clinical and epidemiologic data of dialysis patients which may be applied to other settings and provides information that can contribute to guiding clinical practice and health care policy.
报告了一个基于网络的平台收集巴西接受维持性透析患者数据的方法和初步结果。
为透析中心提供管理软件的公司对其系统进行了调整，以符合巴西肾脏病学会的处方集。2011年至2017年，患者的基线和随访个人数据每月通过互联网传输至协调中心。
73个透析中心提供了24930名患者的信息：57%为男性，28%年龄在64岁及以上，13%超重/肥胖。透析中位时间为28个月。血液透析是最常见的初始治疗方法（93%），64%的病例使用静脉导管。传统血液透析仍是主要的当前治疗方法（90%）。丙型肝炎、乙型肝炎和艾滋病毒的血清阳性率分别为2.7%、1.1%和0.5%。促红细胞生成素（53.9%）、铁剂（35.1%）和司维拉姆（23.4%）是最常用的药物。血红蛋白<100g/L和血清磷>1.74mmol/L分别出现在33.1%和36.6%的病例中。新发病例（n=7538）的5年生存率为57%。
该倡议是收集透析患者临床和流行病学数据的创新策略，可应用于其他环境，并提供有助于指导临床实践和卫生保健政策的信息。
